

trials@uspto.gov

IPR2016-00510, Paper No. 43  
IPR2016-00512, Paper No. 36  
IPR2016-00514, Paper No. 37  
IPR2016-00516, Paper No. 36  
IPR2016-00517, Paper No. 36  
April 28, 2017

571-272-7822

UNITED STATES PATENT AND TRADEMARK OFFICE

-----  
BEFORE THE PATENT TRIAL AND APPEAL BOARD  
-----

MYLAN PHARMACEUTICALS, INC. and  
MYLAN LABORATORIES LIMITED,

Petitioner,

V.

UCB PHARMA GMBH,  
Patent Owner.

-----  
Case IPR2016-00510 (Patent 6,858,650 B1)  
IPR2016-00512 (Patent 7,384,980 B2)  
IPR2016-00514 (Patent 7,855,230 B2)  
IPR2016-00516 (Patent 8,338,748 B2)  
IPR2016-00517 (Patent 7,985,772 B2)  
-----

BEFORE KRISTINA M. KALAN, ROBERT A. POLLOCK, and  
MICHELLE N. ANKENBRAND, Administrative Patent Judges

Reported By: Paul P. Smakula Patent hearing, held at the offices of:  
UNITED STATES PATENT & TRADEMARK OFFICE MADISON  
BUILDING 600 Dulany Street Alexandria, Virginia 22314

IPR2016-00510 (Patent 6,858,650)  
IPR2016-00512 (Patent 7,384,980 B2)  
IPR2016-00514 (Patent 7,855,230 B2)  
IPR2016-00516 (Patent 8,338,748 B2)  
IPR2016-00517 (Patent 7,985,772 B2)

A P P E A R A N C E S

ON BEHALF OF THE PETITIONER:

CLAY D. HOLLOWAY, ESQUIRE

NITA GRAY, ESQUIRE

KILPATRICK TOWNSEND & STOCKTON, LLP

1100 Peachtree Street, Northeast

Suite 2800

Atlanta, Georgia 30309

(404) 541-6667

ON BEHALF OF THE PATENT OWNER:

JEFFREY OELKE, ESQUIRE

JAMES T. TRAINOR, ESQUIRE

WHITE & CASE, LLP

1155 Avenue of the Americas

New York, New York 10020

(212) 819-8580

IPR2016-00510 (Patent 6,858,650)  
IPR2016-00512 (Patent 7,384,980 B2)  
IPR2016-00514 (Patent 7,855,230 B2)  
IPR2016-00516 (Patent 8,338,748 B2)  
IPR2016-00517 (Patent 7,985,772 B2)  
A P P E A R A N C E S   C O N T I N U E D

ON BEHALF OF ALEMBIC:

MANISH MEHTA, ESQUIRE

BENESCH, FRIEDLANDER, COPLAND & ARONOFF, LLP

333 West Wacker Drive

Suite 1900

Chicago, Illinois 60606

(312) 212-4953

ON BEHALF OF AMERIGAN:

WILLIAM D. HARE, ESQUIRE

5335 Wisconsin Avenue, Northwest

Suite 440

Washington, DC 20015

(202) 640-1801

IPR2016-00510 (Patent 6,858,650)  
IPR2016-00512 (Patent 7,384,980 B2)  
IPR2016-00514 (Patent 7,855,230 B2)  
IPR2016-00516 (Patent 8,338,748 B2)  
IPR2016-00517 (Patent 7,985,772 B2)

PROCEEDINGS

JUDGE ANKENBRAND: Good afternoon, everyone.

We have this morning our consolidated final hearing  
in IPR2016-510, -512, -514, -516, and  
-517 between Petitioners Mylan Pharmaceuticals,  
Inc. and Mylan Laboratories and Patent Owner UCB  
Pharma GMBH. I also note for the record that  
Petitioners Alembic Pharmaceuticals Limited, Torrent  
Pharmaceuticals Limited, and Amerigen Pharmaceuticals  
have been joined as Petitioners to the 510 IPR.

I'm Judge Ankenbrand. I'm joined by Judge  
Pollock and Judge Kalan, who's appearing remotely  
from our Denver office.

Counsel, can you please introduce yourself and  
let us know who will be presenting for today? We will  
start with Petitioner Mylan. Before you introduce  
yourself, we want to let counsel know that we  
received a response to our order that we issued on  
Monday requesting an explanation for Mr. Stockwell's

IPR2016-00510 (Patent 6,858,650)  
IPR2016-00512 (Patent 7,384,980 B2)  
IPR2016-00514 (Patent 7,855,230 B2)  
IPR2016-00516 (Patent 8,338,748 B2)  
IPR2016-00517 (Patent 7,985,772 B2)

1 absence from the hearing today, and we accept the  
2  
3 representations in that filing.  
4

5 MR. HOLLOWAY: Clay Holloway on behalf of  
6  
7 Petitioners Mylan.  
8

9 JUDGE ANKENBRAND: Good afternoon.  
10

11 MR. HOLLOWAY: And this is Ms. Gray, she'll be  
12  
13 helping with the presentation.  
14

15 JUDGE ANKENBRAND: Okay. Will counsel for the  
16  
17 joined Petitioners please introduce themselves for the  
18  
19 record. We can start with counsel for Alembic.  
20

21 MR. MEHTA: Menish Mehta on behalf of Alembic.  
22

23 JUDGE ANKENBRAND: Good afternoon. And for  
24  
25 Torrent? Anyone here from Torrent? [no response] And how about  
26  
27 Amerigen?  
28

29 MR. HARE: Bill Hare for Amerigen. I'm here  
30  
31 with Jonathan Embleton, Amerigen.  
32

33 JUDGE ANKENBRAND: All right. Good afternoon.  
34  
35 And for the Patent Owner today, who do we have?  
36

37 MR. OELKE: Your Honor, I'm Jeff Oelke from

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.